188 related articles for article (PubMed ID: 37282729)
21. Engineering Natural Killer Cells for Cancer Immunotherapy.
Rezvani K; Rouce R; Liu E; Shpall E
Mol Ther; 2017 Aug; 25(8):1769-1781. PubMed ID: 28668320
[TBL] [Abstract][Full Text] [Related]
22. Reformation in chimeric antigen receptor based cancer immunotherapy: Redirecting natural killer cell.
Lin C; Zhang J
Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):200-215. PubMed ID: 29378229
[TBL] [Abstract][Full Text] [Related]
23. Clinical development of natural killer cells expressing chimeric antigen receptors.
Golden RJ; Fesnak AD
Transfus Apher Sci; 2021 Feb; 60(1):103065. PubMed ID: 33468407
[TBL] [Abstract][Full Text] [Related]
24. Cancer Immunotherapy Based on Natural Killer Cells: Current Progress and New Opportunities.
Hu W; Wang G; Huang D; Sui M; Xu Y
Front Immunol; 2019; 10():1205. PubMed ID: 31214177
[TBL] [Abstract][Full Text] [Related]
25. NK cell therapy in relapsed refractory multiple myeloma.
Roshandel E; Ghaffari-Nazari H; Mohammadian M; Salimi M; Abroun S; Mirfakhraie R; Hajifathali A
Clin Immunol; 2023 Jan; 246():109168. PubMed ID: 36415020
[TBL] [Abstract][Full Text] [Related]
26. Chimeric antigen receptor- and natural killer cell receptor-engineered innate killer cells in cancer immunotherapy.
Zhang C; Hu Y; Xiao W; Tian Z
Cell Mol Immunol; 2021 Sep; 18(9):2083-2100. PubMed ID: 34267335
[TBL] [Abstract][Full Text] [Related]
27. Chimeric Antigen Receptor-Natural Killer Cells: A New Breakthrough in the Treatment of Solid Tumours.
Pan S; Wang F; Jiang J; Lin Z; Chen Z; Cao T; Yang L
Clin Oncol (R Coll Radiol); 2023 Mar; 35(3):153-162. PubMed ID: 36437159
[TBL] [Abstract][Full Text] [Related]
28. Chimeric antigen receptor-engineered natural killer cells: a promising cancer immunotherapy.
Chaudhry K; Dowlati E; Bollard CM
Expert Rev Clin Immunol; 2021 Jun; 17(6):643-659. PubMed ID: 33821731
[No Abstract] [Full Text] [Related]
29. Selective Cytotoxicity of Single and Dual Anti-CD19 and Anti-CD138 Chimeric Antigen Receptor-Natural Killer Cells against Hematologic Malignancies.
Luanpitpong S; Poohadsuan J; Klaihmon P; Issaragrisil S
J Immunol Res; 2021; 2021():5562630. PubMed ID: 34337077
[TBL] [Abstract][Full Text] [Related]
30. Inhibition-Resistant CARs for NK Cell Cancer Immunotherapy.
Zhuang X; Long EO
Trends Immunol; 2019 Dec; 40(12):1078-1081. PubMed ID: 31732285
[TBL] [Abstract][Full Text] [Related]
31. Inability of granule polarization by NK cells defines tumor resistance and can be overcome by CAR or ADCC mediated targeting.
Eitler J; Wotschel N; Miller N; Boissel L; Klingemann HG; Wels W; Tonn T
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33468562
[TBL] [Abstract][Full Text] [Related]
32. Breast cancer immunotherapy: a comprehensive review.
Keshavarz S; Wall JR; Keshavarz S; Vojoudi E; Jafari-Shakib R
Clin Exp Med; 2023 Dec; 23(8):4431-4447. PubMed ID: 37658246
[TBL] [Abstract][Full Text] [Related]
33. Challenges of chimeric antigen receptor-T/natural killer cell therapy in the treatment of solid tumors: focus on colorectal cancer and evaluation of combination therapies.
Wang H; Pan W
Mol Cell Biochem; 2023 May; 478(5):967-980. PubMed ID: 36190614
[TBL] [Abstract][Full Text] [Related]
34. Off-the-Shelf Prostate Stem Cell Antigen-Directed Chimeric Antigen Receptor Natural Killer Cell Therapy to Treat Pancreatic Cancer.
Teng KY; Mansour AG; Zhu Z; Li Z; Tian L; Ma S; Xu B; Lu T; Chen H; Hou D; Zhang J; Priceman SJ; Caligiuri MA; Yu J
Gastroenterology; 2022 Apr; 162(4):1319-1333. PubMed ID: 34999097
[TBL] [Abstract][Full Text] [Related]
35. CAR NK Cell Therapy for the Treatment of Metastatic Melanoma: Potential & Prospects.
Hibler W; Merlino G; Yu Y
Cells; 2023 Nov; 12(23):. PubMed ID: 38067178
[TBL] [Abstract][Full Text] [Related]
36. Highly Efficient Generation of Transgenically Augmented CAR NK Cells Overexpressing CXCR4.
Jamali A; Hadjati J; Madjd Z; Mirzaei HR; Thalheimer FB; Agarwal S; Bonig H; Ullrich E; Hartmann J
Front Immunol; 2020; 11():2028. PubMed ID: 32983147
[TBL] [Abstract][Full Text] [Related]
37. Preclinical and clinical studies of CAR-NK-cell therapies for malignancies.
Li H; Song W; Li Z; Zhang M
Front Immunol; 2022; 13():992232. PubMed ID: 36353643
[TBL] [Abstract][Full Text] [Related]
38. Natural killer cells in clinical development as non-engineered, engineered, and combination therapies.
Lamers-Kok N; Panella D; Georgoudaki AM; Liu H; Özkazanc D; Kučerová L; Duru AD; Spanholtz J; Raimo M
J Hematol Oncol; 2022 Nov; 15(1):164. PubMed ID: 36348457
[TBL] [Abstract][Full Text] [Related]
39. Fourth-generation chimeric antigen receptor T cells targeting folate receptor alpha antigen expressed on breast cancer cells for adoptive T cell therapy.
Luangwattananun P; Junking M; Sujjitjoon J; Wutti-In Y; Poungvarin N; Thuwajit C; Yenchitsomanus PT
Breast Cancer Res Treat; 2021 Feb; 186(1):25-36. PubMed ID: 33389403
[TBL] [Abstract][Full Text] [Related]
40. CAR-expressing NK cells for cancer therapy: a new hope.
Xia J; Minamino S; Kuwabara K
Biosci Trends; 2020 Nov; 14(5):354-359. PubMed ID: 32893255
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]